StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Prevymis (letermovir by Quarter

Prevymis (letermovir — CMV prophylaxis) — International reported growth YoY (%) (%)

QuarterlyAnnual

Merck Prevymis (letermovir: 31.0% in Q2 2026, up 15.0 pts from a year earlier.

Latest, Q2 2026
31.0%
Period ended Jun 30, 2026
Change on a year earlier
+15.0 pts
16.0% in Q2 2025
History
20 quarters
Since Q1 2020
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Prevymis | 295 | 228 | 29 | 147 | 115 | 28 | 148 | 113 | 31”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrevymis (letermovir — CMV prophylaxis) — International reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202631.0%+15.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202533.0%+21.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202529.0%+5.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202516.0%-3.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 20256.0%-27.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202412.0%-38.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202424.0%-11.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202419.0%-27.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202433.0%–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202350.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202335.0%+21.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202346.0%–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q3 2022Sep 30, 202214.0%-10.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2022Mar 31, 202215.0%-26.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202121.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 202124.0%-77.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗

Cite this data

StockData. (2026). Merck Prevymis (letermovir (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-prevymis-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.